Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug

• 

  Chancellor and BoE governor call for UK to rebuild ties with EU

  Business - Financial Times - 1 hour ago
• 

  Britain’s bold plan to create super funds

  Business - Financial Times - 6 hours ago

• Biogen’s stock hit by soft sales of Alzheimer’s treatment

  Business - MarketWatch - October 30

• Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction

  Business - CNBC - October 30
• 

  UK regulator approves second Alzheimer's drug in months but government won't pay for it

  Health - ABC News - October 23
• 

  UK regulator approves second Alzheimer's drug in months but government won't pay for it

  World - ABC News - October 23

• Boeing’s stock reverses lower after announcing a $19 billion capital raise

  Business - MarketWatch - October 28
• 

  NHS will not fund new drug to slow Alzheimer’s

  Top stories - BBC News - October 23

More from MarketWatch

• These tips for investing in mutual funds and ETFs keep your portfolio plugged in

  Business - MarketWatch - 30 minutes ago

• Why these ‘Trump trade’ ETF winners are fading — and what it says about the financial markets

  Business - MarketWatch - 57 minutes ago

• ‘I’m 38 and completely broke’: I earn $50,000 a year. What professional degree will guarantee me six figures?

  Business - MarketWatch - 1 hour ago

• ‘I handle my dad’s finances’: My father is in a nursing home and will get $100K in compensation. What should I do with it?

  Business - MarketWatch - 1 hour ago

• Tesla is new pick for Daniel Loeb’s Third Point, as hedge fund ditches Uber

  Business - MarketWatch - 1 hour ago